

Niloufer Khan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6526141/publications.pdf>

Version: 2024-02-01

26
papers

1,919
citations

759233

12
h-index

752698

20
g-index

26
all docs

26
docs citations

26
times ranked

3659
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. <i>New England Journal of Medicine</i> , 2016, 375, 2023-2036.	27.0	663
2	Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. <i>BMJ: British Medical Journal</i> , 2018, 360, k793.	2.3	438
3	Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2020, 382, 822-834.	27.0	435
4	Psychological morbidities in adolescent and young adult blood cancer patients during curative-intent therapy and early survivorship. <i>Cancer</i> , 2016, 122, 954-961.	4.1	60
5	The Evolving Role of Radiation Therapy in the Management of Malignant Melanoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 645-654.	0.8	58
6	Future of radiation therapy for malignant melanoma in an era of newer, more effective biological agents. <i>OncoTargets and Therapy</i> , 2011, 4, 137.	2.0	46
7	Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study. <i>Blood</i> , 2021, 137, 1527-1537.	1.4	42
8	Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors. , 2020, 8, e000260.		33
9	Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2257-2265.	1.6	32
10	Single agents vs combination chemotherapy in relapsed and refractory peripheral T-cell lymphoma: Results from the comprehensive oncology measures for peripheral T-cell lymphoma treatment (COMPLETE) registry. <i>American Journal of Hematology</i> , 2019, 94, 641-649.	4.1	25
11	Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2017, 58, 2127-2133.	1.3	20
12	Plaque Brachytherapy for Uveal Melanoma: A Vision Prognostication Model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, e285-e290.	0.8	18
13	The experience of financial toxicity among advanced melanoma patients treated with immunotherapy. <i>Journal of Psychosocial Oncology</i> , 2021, 39, 285-293.	1.2	18
14	Where Do the New Drugs Fit in for Relapsed/Refractory Hodgkin Lymphoma?. <i>Current Hematologic Malignancy Reports</i> , 2017, 12, 227-233.	2.3	8
15	Peripheral T-cell lymphoma "are we making progress?. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 306-314.	1.7	8
16	Patient preferences for first-line treatment of classical Hodgkin lymphoma: a US survey and discrete choice experiment. <i>Leukemia and Lymphoma</i> , 2020, 61, 2630-2637.	1.3	8
17	A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma. <i>Blood</i> , 2019, 134, 4033-4033.	1.4	2
18	TP53 Mutations Identify High-Risk Peripheral T-Cell Lymphoma Patients Treated with CHOP-Based Chemotherapy. <i>Blood</i> , 2021, 138, 1367-1367.	1.4	2

#	ARTICLE	IF	CITATIONS
19	Interim Efficacy Analysis of a Phase II Study Demonstrates Promising Activity of the Combination of Pembrolizumab (PEM) and Entinostat (ENT) in Relapsed and Refractory (R/R) Hodgkin Lymphoma (HL). Blood, 2021, 138, 2447-2447.	1.4	1
20	Clinical outcomes with use of radiation therapy and risk of transformation in early-stage follicular lymphoma. Blood Cancer Journal, 2022, 12, 29.	6.2	1
21	Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Cutaneous T Cell Lymphoma. Journal of Palliative Medicine, 2022, 25, 958-963.	1.1	1
22	Immunotherapy in mycosis fungoides: opening night or dress rehearsal?. Leukemia and Lymphoma, 2019, 60, 864-866.	1.3	0
23	Impact of Choice of Platinum-Based Salvage Therapy on CNS Relapse in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 2529-2529.	1.4	0
24	Clinical Outcomes and CNS Relapse Risk in Patients with Primary Cutaneous DLBCL, Leg Type Treated in the Rituximab Era: Long-Term Follow-up of a Single-Center Experience. Blood, 2021, 138, 2513-2513.	1.4	0
25	Favorable Outcomes of Patients with Limited-Stage Ocular Adnexal DLBCL Treated in the Rituximab Era: Long-Term Follow-up of a Single Center Experience. Blood, 2021, 138, 4578-4578.	1.4	0
26	How we treat mycosis fungoides and SÄ©zary syndrome. Clinical Advances in Hematology and Oncology, 2021, 19, 573-581.	0.3	0